Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces Boulardii CNCM I-745 in IBS with SIBO
NCT04627337Phase 4Completed
- Sponsor
- CEMIC
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of saccharomyces boulardii in Irritable bowel syndrome with diarrhea (IBS-D), small intestinal bacterial overgrowth (SIBO), sponsored by CEMIC. Started Feb 2017; status: completed.
02
Drugs
saccharomyces boulardii
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT04627337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627337.